Jupiter Endovascular Completes SPIRARE II Trial Enrolment for Vertex System

SPIRARE II Pivotal Trial of Jupiter’s Vertex Pulmonary Embolectomy System Completes Enrollment

February 5, 2026—Jupiter Endovascular, Inc. announced completion of patient enrollment in the SPIRARE II pivotal clinical trial evaluating the company’s Vertex pulmonary embolectomy system in patients with acute, intermediate-risk pulmonary embolism (PE). The final patient was enrolled by interventional cardiologist Vikas Aggarwal, MD, at Henry Ford Hospital in Detroit, Michigan. According to Jupiter Endovascular, SPIRARE II is a prospective, si…

Jupiter Endovascular completes SPIRARE II trial enrolment for Vertex system

Jupiter Endovascular has completed patient enrolment in the SPIRARE II pivotal clinical trial of its Vertex pulmonary embolectomy (PE) system.The post Jupiter Endovascular completes SPIRARE II trial enrolment for Vertex system appeared first on Medical Device Network.

Jupiter Endovascular completes enrolment in SPIRARE II pivotal trial

Vertex PE system Jupiter Endovascular today announced completion of patient enrolment in the SPIRARE II pivotal clinical trial evaluating the Vertex pulmonary embolectomy system in patients with acute, intermediate-risk pulmonary embolism (PE). The final subject was enrolled by Vikas Aggarwal at Henry Ford Hospital in Detroit, USA—the site’s principal investigator. SPIRARE II is a prospective, single-arm, multicentre pivotal study that has enrol…